Background. Evidence indicates that a transfusion (Tx) trigger hemoglobin (Hgb) value of 8 gm/dL may be safer than a more liberal Tx trigger in cardiac surgery (CS) patients. We hypothesized that weekly physician feedback would improve adherence to such a protocol, but that the public identification of individual physician behavior would have an additive effect.
Background. Evidence indicates that a transfusion (Tx) trigger hemoglobin (Hgb) value of 8 gm/dL may be safer than a more liberal Tx trigger in cardiac surgery (CS) patients. We hypothesized that weekly physician feedback would improve adherence to such a protocol, but that the public identification of individual physician behavior would have an additive effect.
Methods. We concurrently reviewed all adult CS patients at our institution from December 1, 2010 to May 27, 2011. We matched any cardiac surgery intensive care unit Tx event (red blood cells) with the Hgb value immediately before Tx. Patients requiring massive transfusions (>10 units/24 hours) were excluded. After all providers agreed upon a Hgb of 8 as the Tx trigger, we studied 3 consecutive time periods: no feedback, weekly feedback of group Tx behavior, and weekly feedback with identification of individual surgeon Tx behavior.
Results. Of the 512 patients who underwent cardiac operations, 144 patients underwent 510 Tx events.
Compared with period 1, the unadjusted odds of receiving a Tx above 8 gm/dL decreased by 48% in study period 2(odds ratio: 0.52, p < 0.01), and 63% in study period 3(odds ratio: 0.37, p <0.001). Single unit transfusion rates increased from 77% to greater than 90% (p < 0.001). In-hospital mortality also fell from period 1 to period 3 (7.0% to 1.5%, p [ 0.02) with the observed to expected mortality ratio decreasing from 2.19 to 0.51.
Conclusions. Blood transfusion protocol adherence improves when weekly feedback is provided. Identifying individual surgeon behavior improves adherence to a greater degree. Routine presentation of quality metrics with identification of individual physician-specific behavior may be the most effective way to accomplish performance improvement.
(Ann Thorac Surg 2013;96:2168-74) Ó 2013 by The Society of Thoracic Surgeons B lood transfusions are not without risks [1] [2] [3] [4] [5] [6] [7] [8] [9] , and evidence is increasing that a restrictive transfusion policy in intensive care and surgical patients is at least equivalent to a more liberal transfusion policy [4, [6] [7] [8] . Nevertheless, transfusion practices remain largely unchanged, demonstrating the inherent difficulty in modifying physician behavior. We undertook this performance improvement project to evaluate whether a restrictive transfusion protocol for cardiac surgery patients could be incorporated into clinical practice. We hypothesized that cardiac surgeons' behavior could be modified through group feedback and further modified through identification of individual surgeon behavior to the group (peer disclosure).
Material and Methods

Study Design
This study was approved under Institution Review Board protocol: NA_00001068. This protocol allows for reviews of outcomes of all cardiac surgical procedures at the Johns Hopkins Hospital.
Patient Selection
We concurrently reviewed our prospective database to identify adult patients (!18 years) undergoing cardiac surgery between December 1, 2010 and May 27, 2011 and subsequently transferred to the cardiac surgical intensive care unit (CSICU). All packed red blood cell transfusions occurring in the CSICU in this population were recorded, as were hemoglobin (Hgb) levels immediately prior to transfusion. Only patients who received greater than 10 units within 24 hours (massive transfusion) were excluded from analysis.
Protocol Selection
Prior to the onset of this study, a consensus was reached among our cardiac surgeons and our cardiac critical care providers that a hemoglobin level of less than 8 gm/dL would be utilized as our transfusion trigger. This trigger was utilized during the entirety of this study.
Transfusion Authorization
In our co-managed ICU, both cardiac surgery attendings, cardiac residents, and ICU providers (intensivists, surgery residents, and mid-level providers) have the ability to order a transfusion. However, after initiation of the transfusion protocol, only the attending surgeon, cardiac resident, or intensivist could order a transfusion. Additionally, intensivists communicated with the cardiac attending or resident prior to administering transfusions. Cardiac resident authorized transfusions were presumed to be due to attending surgeon specifications.
Stratification
We stratified our patient population into 2 groups, transfused and non-transfused. Our study was stratified into the following 3 periods: period 1 (week 1 to week 8), cardiac surgical provider transfusion practices were observed without any feedback regarding protocol adherence; period 2 (week 9 to week 15), providers were given weekly feedback regarding group, but not individual provider, protocol adherence; and period 3 (week 16 to week 25), providers were given weekly feedback, as a group, but with disclosure of individual cardiac surgeon behavior. All feedback (periods 2 and 3) was given publicly at a weekly cardiac surgical division meeting.
Transfused patients were primarily stratified by hemoglobin levels at the time of transfusion. Secondary stratification (in period 3) was by surgical provider.
Outcomes
Our primary outcome of interest was protocol adherence. Secondary outcomes included the percentage of single unit transfusions, change in creatinine at discharge compared with preoperative levels, CSICU length of stay (LOS), total hospital LOS, and in-hospital mortality. Additionally, for each study period the observed mortality to expected mortality ratio was determined.
Statistics
Baseline differences in demographic and operative variables among study periods were compared using the Student t test or analysis of variance for normally distributed continuous variables. 
Results
Cohort Characteristics
During our 25 week study, 524 patients underwent cardiac surgery. Of these, 156 underwent 726 ICU transfusions. After excluding mass transfusions (>10 units in 24 hours), our final cohort consisted of 512 patients, with 144 undergoing 510 packed red blood cell transfusion events.
The mean age of the cohort was 60.2 AE 15.5 years, 325 (63.5%) were male, with 154 (30.1%) having diabetes and 338 (66.0%) hypertension. Isolated coronary artery bypass grafting procedures were performed in 161 (31.4%). Mean cardiopulmonary bypass time was 110.9 AE 50.1 minutes.
Stratified Cohort Characteristics
In comparing transfused and non-transfused patients for all 3 study periods, transfused patients had a higher preoperative creatinine (p ¼ 0.02). They also had a greater predicted mortality risk (p < 0.01), longer bypass times (p ¼ 0.02), and more intraoperative transfusions (p ¼ 0.02, Table 1 ).
Stratification of the transfused group by study period showed that nearly all variables were evenly distributed. Period 2 had fewer patients who were anticoagulated or received antiplatelet therapy prior to surgery (p ¼ 0.02) when compared with periods 1 and 3. Period 3 had fewer patients with cerebrovascular disease (p ¼ 0.049). No other significant differences existed between groups.
Outcomes
Analysis of our primary outcome revealed that the incidence of off-protocol transfusions (transfusion trigger ! 8 gm/dL) decreased significantly over the 3 periods (p <0.001; Fig 1) . Logistic regression analysis demonstrated a 48% decrease in the unadjusted odds of receiving a transfusion above a trigger of 8 gm/dL in period 2 and a 63% decrease in period 3 ( p¼ 0.003 and <0.001, respectively, Table 2 ). Furthermore, the odds of receiving a transfusion with a trigger greater than 9 gm/dL decreased significantly by period 3 (odds ratio: 0.50, p ¼ 0.04). The number of transfused patients with a trigger greater than10 gm/dL showed a decreasing trend but did not reach significance, almost certainly due to small numbers. Finally, single unit transfusions increased (p < 0.001; Fig 2) , although there was no difference between study periods 2 and 3.
To determine whether harm was associated with protocol adherence, we assessed in hospital mortality, change in creatinine, and LOS across study periods. In-hospital mortality did not increase but decreased during the study, with a gross mortality of 7.0%, 2.2%, and 1.5% for study periods 1, 2, and 3, respectively (p ¼ 0.02; Table 3 ). In the transfused cohort, mortality also decreased (p ¼ 0.02) and, in fact, was responsible for the difference in mortality seen across the study periods. There was no significant difference in mortality in the non-transfused cohorts during the study (p ¼ 0.39; Table 4 ). The observed to expected mortality across the study periods revealed a nonsignificant decrease, falling from 2.19 to 0.51 (p ¼ 0.15; Table 3 ), with no significant differences in change in creatinine, ICU LOS, or overall LOS across study periods in either cohort (Table 4) .
Comment
Both the incidence of off-protocol transfusions and the univariate odds of giving a transfusion for an Hgb trigger 8 gm/dL or greater decreased as the study progressed. Additionally, single unit transfusions increased. More restrictive behavior did not adversely affect patients, but rather was associated with a decrease in in-hospital mortality from study period 1 to period 3.
The documented risks of blood product transfusions include fever, lung injury, circulatory overload, sepsis, hemolytic transfusion reactions, and infectious complications [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] . Furthermore, transfused patients appear to suffer an increased mortality compared with non-transfused patients, with mortality curves continuing to separate through 5 years of follow-up [3, 13, 14] . Although many strategies aim at reducing the risks associated with these transfusions, the most effective manner of avoiding a transfusion complication is to avoid the transfusion [10] Although the risks associated with transfusions are well known, consensus on the most appropriate Hgb trigger for a transfusion is not uniformly agreed upon despite evidence that restrictive strategies appear as safe as liberal ones.
Only 4 randomized controlled trials have investigated the subject of restrictive strategies in blood transfusions. In perhaps the most well known, the Transfusion Requirements in Critical Care trial of 1999, H ebert and colleagues [6] analyzed 838 ICU patients, both medical and surgical, and randomized them to blood transfusions based on either a Hgb trigger of 7 or 10 gm/dL. They found equivalent all-cause 30-day mortalities between groups, with decreased in-hospital mortality in the restrictive cohort. Subgroup analyses showed that younger patients, as well as patients with lower APACHE [Acute Physiology and Chronic Health In the most recent randomized trial of a restrictive versus a liberal transfusion trigger (7 vs 9 gm/dL) in patients with upper gastrointestinal bleeds, the restrictive strategy had a higher 45-day survival (95% vs 90%) as well as a lower rate of further bleeding [15] . There is only 1 randomized control trial in cardiac surgery examining transfusion triggers. In that study from 2010, Hajjar and colleagues [7] examined 512 consecutive open heart surgery patients, including coronary bypass, valve surgery, and combined procedures. Patients were randomized to a hematocrit transfusion trigger of 24% versus 30%. They found no difference in 30-day mortality or the incidence of severe postoperative morbidity. However, the lower transfusion trigger value led to a decrease in the transfusion rate from 78% to 47% and an overall decrease in red blood cell utilization by over 50%. Additionally, the number of transfusions remained a significant hazard for mortality and complications, with each transfusion increasing the risk of death at 30 days by 20%. Taking into consideration the risks and benefits of transfusion, the Society of Thoracic Surgeons revised their clinical practice guidelines for blood transfusions in 2011 [13] , noting that transfusions with Hgb values greater than10 gm/dL are unlikely to be useful, while transfusions for Hgb values less than 7 gm/dL are likely reasonable. Despite these recommendations, the transfusion behaviors of cardiac surgery programs throughout this country are widely disparate [2, 5. 9] . In an attempt to standardize practice, there has been a suggestion that transfusion rates be made public, as a measure of quality of care [2] .
Several techniques have been attempted to modify physician behavior in the literature, including physician education, feedback (including peer disclosure), and systems initiatives (eg, prompts in the electronic medical record or use of check lists) [16] [17] [18] [19] [20] [21] [22] [23] . Regionally, the Center for Medicare and Medicaid Services has leveraged the publication of hospital performance metrics to the lay public, presuming that inter-hospital comparisons on websites such as www.hospitalcompare.hhs.gov would improve physician adherence to known evidence-based practice. Furthermore, incentivizing hospitals to improve performance is an ongoing effort [24] . Though the results of these interventions vary widely, with many demonstrating both poor short-term and longterm results, the most favorable results are generally produced in studies which incorporate multiple intervention modalities that are repeated regularly [20, 21] . Additionally, studies which utilized peer disclosure appeared to have larger short-term gains and sustained long-term outcomes [16, 20] .
In our study, we attempted to modify physician transfusion behavior first by education, at which time a consensus was reached regarding an acceptable transfusion trigger. Despite agreement on a trigger value of 8 gm/dL, initial protocol adherence was extremely poor. However, upon weekly presentation of adherence data to the surgeons and providers, presented as group behavior, adherence to the protocol improved. Upon withdrawal of the anonymity of the data in period 3, specifically revealing the transfusion behavior associated with each individual surgeon, we saw further significant improvement in protocol adherence. Perhaps more significantly, our data demonstrate that no harm occurred to patients when a more restrictive transfusion strategy was observed. When normalized for expected mortality, there was a trend for decreased mortality across the study, with a significant decrease in gross mortality. While a decrease in in-hospital mortality is consistent with data from H ebert and colleagues [6] , the observed effect in this study is most likely due to the relatively small sample size. Therefore, although it is difficult to ascribe a benefit in mortality to the restrictive strategy, we believe that it is very clear that no harm was caused by withholding transfusions. Moreover, in our nontransfused patients stratified by study period, no significant differences in mortality or other secondary outcomes over the course of the study were observed as a result of withholding a transfusion, emphasizing that a restrictive policy carries no harm.
Additionally, our data demonstrated an increased incidence in single unit transfusions as the study progressed. Studies have demonstrated that elevated transferrin saturation is associated with acute kidney injury, suggesting that transfusion-related iron overload may be implicated in renal dysfunction [25] . Although no clinical difference in renal function was identified among cohorts during this study, theoretically renal injury may be minimized with single versus multiple unit transfusions.
Limitations
There are several limitations to our study. First, transfusion indications were not addressed by our study. It stands to reason that although a hemoglobin of 8 may be an appropriate value for a protocol-driven approach to transfusion, off-protocol transfusions (when a Hgb is over 8) may be indicated; eg, ongoing bleeding or end organ ischemia. Aiming for a protocol variance of zero might lead to patient harm. Nevertheless, as evidenced by this study, diminishing off-protocol transfusion rates from over 50% to approximately 25% did not jeopardize patient outcome. Understanding the reasons for the variance seen in 1 of 4 transfusions in period 3 could give insight into when the transfusion trigger of 8 should be abandoned. Second, this study does not contain any post-intervention follow-up data and as such can make no comment on post-discharge outcomes as a result of discharging patients with potentially more significant anemia. Third, our assessment of transfusion behavior did not extend to the post-ICU surgical floor. It is possible that transfusions were withheld in the ICU only to be given later on the floor, potentially biasing in hospital mortality and LOS findings. Finally, this study does not account for the possibility that time in and of itself might have been associated with improved transfusion protocol adherence, and that weekly disclosure of transfusion behavior by group or by individual was coincidental to the improvement, not causative. To address this possibility, we divided study periods 2 and 3 into 2 equal length periods and found no difference in protocol adherence during the first half of each study compared with the second half, although the small number in each group makes this comparison vulnerable to a type II error. Nevertheless, this analysis suggests that the duration of the study had less to do with improved protocol compliance than the methodologic differences intrinsic to each study period.
Conclusions
Evidence advocating a restrictive blood transfusion policy is growing. In order to practice evidenced-based medicine, surgeons must adjust their transfusion behavior appropriately. In this study, we assessed the effect of weekly feedback of transfusion behavior, first showing group behavior and then assessing the benefit of publically disclosing individual surgeon behavior. During each study period, transfusion protocol adherence improved, suggesting the following: (1) repetitive group feedback improves physician behavior; and (2) disclosing physician-specific behavior at the time of group feedback has a significant, incremental effect on changing physician behavior. Our patients don't follow the details of our research. They don't discuss unexpected breakthroughs or technical setbacks. They are not always aware of how changes in health care policies impact research funding and lab time. Nonetheless, the advances we make in cardiothoracic surgery touch each and every one of them. New surgical techniques and potent new drugs improve patient health and extend patient lives.
That is an outcome everyone can understand, and it's the one that has continued to push the Thoracic Surgery Foundation for Research and Education (TSFRE) forward since 1988, when it was established as a 501(c)(3) not-forprofit charitable organization. Representatives from the four leading thoracic surgery societies-the American Association for Thoracic Surgery (AATS), The Society of Thoracic Surgeons (STS), the Southern Thoracic Surgical Association (STSA), and the Western Thoracic Surgical Association (WTSA) serve on the TSFRE Board of Directors. The Foundation represents all of thoracic surgery in the United States and its research and educational initiatives support the broad spectrum of thoracic surgery. The mission of TSFRE is to foster the development of surgeon scientists in cardiothoracic surgery; increasing knowledge and innovation to benefit patient care.
Funding basic biomedical research to expand our understanding of thoracic surgery is vitally important. Still, it's only half the battle. The results of such research must be successfully transferred to patient care. There is a compelling need to continue to develop the skills of cardiothoracic surgeons as scientists and as health policy leaders. TSFRE is an organization that is having a steering effect on cardiothoracic surgery through the sponsorship of research projects and the education of surgeons in health care policy.
In its 25-year history, TSFRE support has enabled many young cardiothoracic surgeons to develop successful, independent research careers and improve the care of our patients. To date, TSFRE has funded 143 cardiothoracic surgery research grants, fellowships, and simulation awards, and funded more than 250 Alley-Sheridan Scholarships. Because of your support, many of these individuals are now leaders in the cardiothoracic surgery community. This is a TSFRE legacy in which we can all take pride.
Please help TSFRE continue its legacy by making your 25th Anniversary donation today. Visit www.tsfre.org or contact Priscilla Page, TSFRE Executive Director, at 312-202-5868, or by e-mail at ppage@tsfre.org.
